Image pharmaphorum Editor Views & Analysis Artificial Intelligence for better antibody drugs: ready for... The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion. Views & Analysis Capturing progress in haemophilia care If we look back just 70 years, the prognosis for patients with haemophilia was remarkably different to what it is today. Sales & Marketing Sponsored Unlocking the full power of data for Pharma The value of data has never been greater in healthcare. Patients Endometriosis: hidden suffering and disease burden Improving patient outcomes starts by listening to and understanding their needs. Load more results
Views & Analysis Artificial Intelligence for better antibody drugs: ready for... The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion.
Views & Analysis Capturing progress in haemophilia care If we look back just 70 years, the prognosis for patients with haemophilia was remarkably different to what it is today.
Sales & Marketing Sponsored Unlocking the full power of data for Pharma The value of data has never been greater in healthcare.
Patients Endometriosis: hidden suffering and disease burden Improving patient outcomes starts by listening to and understanding their needs.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.